1/9/1
DIALOG(R)File 351:Derwent WPI
(c) 2001 Derwent Info Ltd. All rts. reserv.
012988710
WPI Acc No: 2000-160563/200014
XRAM Acc No: C01-083140
Synthetic peptide used in protecting animals against foot and
mouth disease virus infections comprises helper T-cell epitope
and foot and mouth disease virus epitope conjugate
Patent Assignee: UNITED BIOMEDICAL INC (UNBI-N)
Inventor: SHEN M; WANG C Y
Number of Countries: 087 Number of Patents: 005
Patent Family:
Patent No Kind Date Applicat No Kind Date Week
WO 9966954 A1 19991229 WO 99US13921 A 19990621 200014
B
AU 9948266 A 20000110 AU 9948266 A 19990621 200025
US 6107021 A 20000822 US 98100600 A 19980620 200042
EP 1089759 A1 20010411 EP 99931845 A 19990621 200121
WO 99US13921 A 19990621
BR 9912178 A 20010410 BR 9912178 A 19990621 200128
WO 99US13921 A 19990621
Priority Applications (No Type Date): US 98100600 A 19980620
Patent Details:
Patent No Kind Lan Pg Main IPC Filing Notes
WO 9966954 A1 E 113 A61K-039/245
Designated States (National): AE AL AM AT AU AZ BA BB BG BR BY
CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ
PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW
Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB
GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW
AU 9948266 A A61K-039/245 Based on patent WO 9966954
US 6107021 A C12Q-001/70
EP 1089759 A1 E A61K-039/245 Based on patent WO 9966954
Designated States (Regional): AT BE CH CY DE DK ES FI FR GB GR
IE IT LI LU MC NL PT SE
BR 9912178 A A61K-039/245 Based on patent WO 9966954
Abstract (Basic): WO 9966954 A1
NOVELTY - Synthetic peptide (I) comprising a foot and
mouth disease virus (FMDV) epitope conjugate to a helper
T-cell epitope and optionally an immunostimulator sequence,
is new.
DETAILED DESCRIPTION - Synthetic peptide (I) comprising a
foot and mouth disease virus (FMDV) epitope conjugate to a
helper T-cell epitope and optionally an immunostimulator
sequence, is new.
The synthetic peptide (I) is selected from a group
comprising:
NKYSASGSGVRGDFGSLAPRVARQLPASFNYGAIK
(a) peptide fragments of the VP1 protein of FMDV strains
other than strain A12 and which are homologous to the amino
acids (aa) 134-168 of the A12 strain;
(b) a peptide having the consensus sequence derived from
the aa sequence of the FMDV VP1 protein from strains A, O or
Asia corresponding to aa 134-168 of the A12 strain;
(c) peptides having the sequence (ii)-(v); and
(d) peptides (i-iv) where the aa at positions 134 and 157
of the FMDV strain A12 VP1 protein are replaced by Cys
residues.
(i) KYX3GX3RGDX3LAXRVX3LPXSFNX
GAX2;
(ii) X22QX3SFNXGAX2;
(iii) X2YX4VX3RGDX3LX3KX2RXLP
X2FNYGAIX;
(iv) X2YGX4RRGDXAXLAERXSX2LPTDFNYG
AVK.
INDEPENDENT CLAIMS are also included for the following:
(1) a peptide comprising the aa sequence of a peptide in
(I) and an aa sequence of a helper T-cell epitope or of a
general immunostimulatory sequence;
(2) a structured synthetic antigen library where the
library consists of multiples of the amino acid sequence
selected from 9 amino acid sequences given in the
specification;
(3) a nucleic acid molecule encoding for a peptide (I);
and
(4) a peptide conjugate represented by the formula (F1):
(A)n-(FMDV antigen)-(B)o-(Th)m-X;
(A)n-(Th)m-(B)o-(FMDV antigen)-X;
(FMDV antigen)-(B)o-(Th)m-(A)n-X;
(Th)m-(B)o-(FMDV antigen)-(A)n-X;
where:
A=an independent aa sequence or general immunostimulatory
sequence
B=-NHCH(X)CH2SCH2CO-, -NHCH(X)CH2SCH2CO(epsilon-N)Lys-,
-NHCH(X)CH2S-succinimidyl(epsilon-N)Lys- or
-NHCH(X)CH2S-(succinimidyl);
Th=a helper T-cell epitope or immune enhancer analog or
segment;
FMDV antigen=an aa sequence selected from the peptides of
(A) or one of 9 aa sequences given in the specification;
X=an aa alpha-COOH or CONH2;
n=0-10;
m=1-4, and
o=0-10.
ACTIVITY - Immunostimulant.
MECHANISM OF ACTION - Vaccine.
USE - The peptide is used to generate an enhanced immune
response against a FMDV antigen in animals, e.g. farm
animals. It can also be used to diagnose FMDV infection in a
mammal.
ADVANTAGE - In contrast to previous vaccines the present
invention requires lower levels of biosecurity, has a reduced
loss of immunogenic activity, are less prone to product
instability and lot-to-lot variability and do not need
periodic revision due to antigenic variation in the field.
pp; 113 DwgNo 0/4
Technology Focus:
TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred peptide: The
peptide is selected from the sequence CKYSASGSGV RGDFGSLAPR
VARCLPASFN YGAIK or homologous sequences derived from the
other strains of FMDV. The peptide may further comprise 1-13
aa from either end of the 134-157 segment of VP1. The VP1
target sequence is selected from one of 17 aa sequences given
in the specification. The Th epitope is selected from known
FMDV Th, known foreign pathogenic Th epitopes, sequences:
KKKIITITRIITIITD;
ISIXGIXXVIVXXIEXILF;
XXEXXGVIVXXX; or
IXEIXXVIVXXIEXI
and their analogs.
A=at least one invasin domain having the sequence
TAKSKKFPSYTATYQF and immunostimulatory analogs or segments of
it
B=is especially the sequence PPXPXP where X is any amino
acid. (A)3 is especially (invasin domain)-Gly-Gly.
Title Terms: SYNTHETIC; PEPTIDE; PROTECT; ANIMAL; FOOT; MOUTH;
DISEASE; VIRUS; INFECT; COMPRISE; HELP; CELL; EPITOPE; FOOT;
MOUTH; DISEASE; VIRUS; EPITOPE; CONJUGATE
Derwent Class: B04; C06; D16
International Patent Class (Main): A61K-039/245; C12Q-001/70
International Patent Class (Additional): A61K-038/00; A61K-039/00
; A61K-039/12
File Segment: CPI
Manual Codes (CPI/A-N): B04-B04C; B04-C01G; B04-E02F; B04-E03F;
B04-F11; B12-K04A4; B14-G01; B14-S11; C04-B04C; C04-C01G;
C04-E02F; C04-E03F; C04-F11; C12-K04A4; C14-G01; C14-S11;
D05-C12; D05-H07; D05-H09; D05-H17
Chemical Fragment Codes (M1):
*01* M421 M431 M710 M782 M905 P434 P831 Q233 RA00NS-T RA00NS-M
RA00NS-N
*02* M421 M431 M710 M782 M905 P434 P831 Q233 RA00H1-T RA00H1-M
RA00H1-N
*03* M421 M423 M431 M710 M782 M905 P434 P831 Q233 RA00H3-T
RA00H3-M RA00H3-N
Specific Compound Numbers: RA00NS-T; RA00NS-M; RA00NS-N; RA00H1-T
; RA00H1-M; RA00H1-N; RA00H3-T; RA00H3-M; RA00H3-N
Key Word Indexing Terms:
*01* 93605-0-0-0-CL, NEW 184611-0-0-0-CL, NEW
184616-0-0-0-CL, NEW
|
